Objective: The aims of this cross-sectional study were to determine if cognitive function differs across stages of reproductive aging and to evaluate whether hormones or menopausal symptoms predict cognition in perimenopause. We hypothesized that women in late menopausal transition and early postmenopause would perform more poorly than those in the late reproductive stage on attention and verbal memory tasks, and that estradiol, depressive symptoms, anxiety symptoms, hot flashes, and sleep disturbance would predict cognitive performance on those tasks.
O ur understanding of the impact of reproductive aging stage on cognitive performance has been significantly advanced in recent years owing to findings from largescale studies of the menopausal transition. In the Kinmen Women_s Health Investigation (KIWI), 573 Chinese women completed five cognitive tests at baseline and 18-month followup. Compared with participants who remained premenopausal, those who entered perimenopause had significantly less improvement in verbal fluency. 1 The Chicago site of the Study of Women_s Health Across the Nation (SWAN) found no effect of menopausal stage on working memory or perceptual speed in a sample of 803 women who completed two or more successive annual evaluations. 2 A subsequent 4-year longitudinal study of 2,362 SWAN participants found an effect of menopausal stage on verbal episodic memory and processing speed, 3 with evidence of decreased verbal episodic memory in the early and late perimenopausal stages and deficits in processing speed in the late perimenopausal stage. Consistent with the earlier SWAN, 2 no effect of stage on a working memory test was observed. 3 Findings from cross-sectional studies with smaller numbers of perimenopausal women, including a study from the Melbourne Women_s Midlife Health Project that consisted of 50 perimenopausal women, show no impact of perimenopausal stage on cognitive function. 4 In general, however, findings from large studies suggest that there are small but measurable objective declines in cognitive function during perimenopause that warrant further investigation.
These apparent discrepant findings may be due, in part, to differing criteria for staging the menopausal transition. In KIWI, perimenopause was defined as irregular menstrual cycles or the last menstrual cycle between 3 and 12 months before study baseline. SWAN defines early perimenopause as decreased predictability of menses but with no gap of 3 months or longer, and late perimenopause as 3 to 11 months of amenorrhea. The Melbourne Women_s Midlife Health Project defines early menopausal transition as changes in menstrual cycles with menstruation in the prior 3 months, and late menopausal transition as 3 to 12 months of amenorrhea. In SWAN, postmenopause was defined as beginning at the final menstrual period (FMP; i.e., at the beginning of the first 12-month period of amenorrhea). In KIWI and the Melbourne Women_s Midlife Health Project, postmenopause was defined as beginning after 12 months of amenorrhea. Recently, an expert group convened to revise the criteria for the onset of late reproductive life and early menopausal transition. 5 Key revisions to this common staging system include refinement of the criteria for entry into late reproductive life, early menopausal transition, and early postmenopausal stages. These revisions have resulted in a finer differentiation between reproductive aging stages and allow us to investigate women experiencing the earliest changes in menstrual cycles and to evaluate finer differences in the early postmenopausal period.
Factors contributing to cognitive decline in the menopausal transition have not yet been clearly identified. It is postulated that fluctuations in endogenous estrogen levels and symptoms associated with the menopausal transition, such as depression, sleep disturbance, and hot flashes, may independently or additively underlie these changes. 6 Estrogen influences hippocampal function, prefrontal cortex (PFC) function, and the cognitive functions subserved by these brain regions, including verbal memory and executive function. 7<10 Studies of midlife women, however, have failed to find a linear relationship between serum hormone levels and cognition. 11<13 A number of observational studies, including SWAN, have failed to find a relationship between self-reported hot flashes and cognitive function. 6, 14, 15 Furthermore, estrogen effects on menopausal symptoms have been shown to be decoupled from cognitive effects. 16, 17 New data from 2,362 SWAN participants demonstrate that differences in cognition across menopausal stages are not caused by differences in menopause symptoms across stages. 6 The present study builds upon these new findings in several ways to understand cognitive function in perimenopause. First, we used a comprehensive battery assessing six cognitive domains. The battery included a measure of verbal memory that has a high ceiling and allows for the assessment of three stages of memory: encoding, storage, and retrieval. The use of a verbal memory measure with a high ceiling is important because many participants in SWAN started with maximal verbal memory scores. 3 Second, we examined cognitive performance as a function of four rather than two or three reproductive aging stages and included women at earlier stages of transition. Third, we examined cognitive change in the context of endogenous sex steroid levels and other menopausal symptoms.
The primary aims of the present study were twofold. First, we sought to determine if cognition in midlife women differed across stages of reproductive aging. We hypothesized that women in late menopausal transition and early postmenopause would perform worse than those in the late reproductive stage on cognitive tasks supported by the hippocampus and PFC. Second, we aimed to determine how menopauserelated factors, including hormone levels, mood, vasomotor symptoms, and sleep quality, impact cognition in perimenopause. We hypothesized that lower levels of estradiol (E 2 ), increased depressive symptoms, increased anxiety, increased hot flashes, and poor sleep quality would all be associated with worse cognitive performance.
METHODS
Data for this study were collected in three waves in a manner that was fully consistent across each wave. Wave I was an unfunded pilot study conducted from January 2005 to December 2006. Wave II was a federally funded study conducted from April 2007 to December 2009. Wave III is an ongoing, federally funded longitudinal study begun in September 2010. Women were recruited to participate in a study of memory in perimenopause. Participants were asked to complete evaluations at baseline, 6-month follow-up, and 1-year follow-up in Waves I and II, and biannual evaluations for 5 years in Wave III. Twenty-four women participated in Wave I, and their baseline data have been reported previously. 16 Fourteen of the 24 women continued their participation, and an additional 51 women were recruited in Wave II. Thirty-seven of these women continued their participation, and an additional 42 were recruited in Wave III, yielding a total sample of 117 women. The baseline data for the entire sample are presented here (24 at Wave I, 51 at Wave II, and 42 at Wave III).
Participants
Participants were recruited through advertisements placed in local newspapers, recruitment posters displayed at local obstetrics/gynecology and primary care clinics affiliated with the University of Rochester Medical Center, and recruitment posters placed throughout the medical center itself. The advertisements and posters described a study of memory in perimenopause but did not specifically target women with memory complaints. Inclusionary criteria were as follows: (a) aged 40 to 60 years; (b) reports changes in menstrual cycles; (c) reports at least one menstrual period in the prior 12 months; and (d) has intact uterus. Exclusion criteria were as follows: (a) history of neurological disease; (b) history of psychiatric illness; (c) surgical menopause; and (d) use of exogenous hormone preparations affecting ovarian or pituitary function in the prior 3 months. All participants completed a written informed consent form. Our study was approved by the University of Rochester Research Subjects Review Board. Participants in Wave II received US$20 for time and travel and free parking, and were eligible for a total of US$75 if they participated in all follow-up evaluations. Participants in Wave III received US$25 for time and travel and free parking, and were eligible for a total of US$250 if they participated in all follow-up evaluations.
Menopausal transition stage
Menopausal transition stage was based on self-reported bleeding patterns according to the Stages of Reproductive Aging Workshop +10 (STRAW +10). 5 Specifically, participants were classified into one of four stages of reproductive aging: (1) late reproductive (j3a): subtle changes in menstrual flow, cycle length, or both; (2) early menopausal transition (j2): persistent cycle irregularity, defined as a difference in the length of consecutive cycles of 7 days or more at least twice during the prior 10 cycles; (3) late menopausal transition (j1): interval of amenorrhea of 60 days or longer; and (4) early postmenopause (1a): the first 12 months after the FMP. The staging categories were mutually exclusive; thus, once participants met criteria for a later stage, they were no longer eligible for the earlier stage. At baseline, we obtained participants_ retrospective self-report of bleeding patterns before study entry. As part of a standard interview, participants were asked the date of their last menstrual period and the average length of their current and past (before perimenopause) menstrual cycles. Given the anchor of the prior 12 months, they were asked to indicate whether they had skipped any periods or undergone a period of amenorrhea, and to provide their shortest and longest cycle lengths. They were also asked to provide information about the lengths of their current and past periods. After the baseline visit, participants tracked their menstrual cycles using monthly calendars on which they recorded all bleeding activities. Thus, we were able to calculate cycle lengths and variability and to determine the timing of FMP to establish group status at later visits. One hundred of our 117 participants had prospective data after the baseline visit; for those participants, we used the selfreported bleeding patterns and the 6-month diary data to determine baseline group status. For eight of those cases, there were discrepancies between baseline self-report and the first 6-month calendar data; thus, staging was based on a consensus between the study investigators using bleeding criteria and hormone levels (follicle-stimulating hormone [FSH] and E 2 ), as recommended by STRAW +10. For the 17 cases in which there were no prospective data, staging was based on baseline self-report of bleeding patterns only. We had 6-month data on 31 of the 41 participants in the late menopausal transition group and thus were able to confirm that they had not experienced their FMP. Of the remaining 10 participants, none had experienced a cycle length of 90 days or longer in the prior 12 months.
Measures
Each participant completed a cognitive battery and self-report questionnaires assessing depression, anxiety, general health, quality of life, and memory function.
Cognitive battery Attention
We assessed basic attention using the Digit Span subtest of the Wechsler Adult Intelligence Scale III. 18 Participants were asked to repeat increasingly longer strings of digitsV first in the order in which the digits were presented (eg, forward) and then in reverse order (ie, backward). The dependent measure was the total number of correct trials. We assessed vigilance/ complex attention using the D2 Test of Attention. 19 Participants were asked to search for targets (a lower-case d with two dots above or below it) in an array of foils (a lower-case d with more than two dots or fewer than two dots, or a lower-case p with any number of dots above or below it) for repeated timed trials. The dependent measure was the total number of items completed minus errors (D2TN j E).
Working memory
We assessed working memory using the Letter-Number Sequencing subtest of the Wechsler Adult Intelligence Scale III. 18 Participants were presented with increasingly longer series of digits and letters, which they had to sequence in a specified order (ie, alphabetical or chronological). Total score was based on the total number of series correctly sequenced.
Verbal fluency
We assessed verbal fluency using the Controlled Oral Word Association. 20 Participants were asked to name as many words as possible beginning with a specified letter (phonemic) and fitting a specified category (semantic) in 1 minute. In this study, the letters FAS and the category animals were used. The dependent measure was the total number of words generated for each task.
Motor
We assessed fine motor skills and dexterity using the Grooved Pegboard Test. 21 Participants were asked to place grooved pegs in a pegboard as quickly as possible. The task was completed once using the dominant hand (grooved pegboard dominant hand [GPDH]) and once using the nondominant hand (grooved pegboard non-dominant hand [GPNDH]). The dependent measure was the time taken to correctly place all of the pegs.
Visuospatial
We assessed visuospatial skills using the Hooper Visual Organization Test. 22 Participants were asked to identify an object that had been cut into pieces and rearranged. The dependent measure was the total number of objects identified correctly.
Memory
We assessed verbal encoding and retention using the Rey Auditory Verbal Learning Test (RAVLT). 23 Participants were presented a list of 15 words on each of five trials. They were then presented a second list of 15 words (interference). Recall of the first (repeated) list was assessed after a short delay (ie, immediately after the interference trial) and again after a 30-minute delay. A forced-choice recognition test followed. The dependent measures were total correct recall from trial 1, total words recalled across the five trials, trial 6 (short delay), trial 7 (long delay), and recognition (hits).
Self-report questionnaires Depression
On the Beck Depression Inventory II, 24 participants rated the intensity of their experience of 21 symptoms of depression during the past 2 weeks using a four-point scale for each item. Each of the 21 items is summed to give a total score. A total score of 0 to 13 is considered minimal depression, a total score of 14 to 19 is considered mild depression, a total score of 20 to 28 is considered moderate depression, and a total score of 29 to 63 is considered severe depression. Higher total scores indicate more severe depression.
Anxiety
On the Beck Anxiety Inventory, 25 participants rated their experience of 21 subjective, somatic, or panic-related symptoms of anxiety on a four-point scale with the following points: BNot at all[ (0); BMildly; it did not bother me much[ (1); BModerately; it was very unpleasant, but I could stand it[ (2); and BSeverely; I could barely stand it[ (3). The items are summed to obtain a total score. A total score of 0 to 7 is considered minimal anxiety, a total score of 8 to 15 is considered mild anxiety, a total score of 16 to 25 is considered moderate anxiety, and a total score of 26 to 63 is considered severe anxiety. Higher total scores indicate more anxiety.
Overall health
On the Women_s Health Questionnaire, 26 The score for each subscale is the total score divided by the total number of items completed, with a maximal score of 1. We used the vasomotor symptoms and sleep problems subscales for this analysis. The vasomotor symptoms subscale includes two items. We assigned the possible scores of 0, 0.5, or 1 as none, mild to moderate symptoms, or severe symptoms, respectively. The sleep problems subscale consists of three items. We assigned the possible scores of 0, 0.33, 0.67, or 1 as none, mild symptoms, moderate symptoms, or severe symptoms, respectively.
Hormone levels
Serum E 2 and FSH levels were collected on the day of cognitive testing. Women who were experiencing monthly periods were examined in the early or midfollicular phase of their cycles (cycle days 4-7). Assays were performed by the clinical laboratory at the University of Rochester Medical Center. Total E 2 and FSH levels were assessed by competitive immunoassay using direct chemiluminescent technology (Advia-Centaur System; Bayer Diagnostics, Tarrytown, NY). The estradiol-6 serum assay has a sensitivity and assay range of 10 to 1,000 pg/mL (36.7-3,670 pmol/L) and a coefficient of variation of 8.1% to 13.6%. The FSH serum assay has a sensitivity and assay range of 0.3 to 200 mIU/mL (IU/L) and a coefficient of variation of 2.9% to 3.9%.
Statistical analyses Composite cognitive domain scores
To reduce the number of statistical comparisons, we created composite z-scores for each domain of cognitive functioning. Attention/working memory consisted of Digit Span, Letter-Number Sequencing, and D2TN j E; executive consisted of letter and category verbal fluency; visuospatial consisted of the Hooper Visual Organization Test; motor consisted of GPDH and GPNDH; verbal learning consisted of RAVLT Trail 1 and total number of words recalled across 5 trials; and verbal memory consisted of RAVLT short-delay, longdelay, and recognition measures. For each of these, we first computed z-scores for individual tests from raw scores and averaged these z-scores for each domain.
Statistical analysis
Before conducting the primary analyses, we first examined the distribution of each cognitive outcome to ensure normality and to check for statistical outliers (ie, values more than 3 SDs above or below the mean). We found two low outliers on the visuospatial domain and one low outlier on the motor domain. There were no significant differences in the results of analyses performed, including and excluding the outliers; thus, results including the outliers are reported here.
To determine if cognition in midlife women differed across stages of reproductive aging and whether menopauserelated factors impacted cognition, we conducted a series of multivariable linear regression analyses. In these models, we included age, years of education, stage of reproductive aging, vasomotor symptoms, sleep symptoms, depression, anxiety, E 2 , and FSH. Based on our hypotheses, our primary focus was comparing each reproductive stage to the late reproductive stage. Exploratory analyses were also conducted to examine each stage relative to the previous stage (late reproductive vs early transition; late transition vs early postmenopause). All P values are two-sided, and the statistical significance level was set to P G 0.05. All analyses were performed using SAS version 9.2 (SAS Institute Inc., Cary, NC).
RESULTS

Cohort characteristics
Table 1 provides demographic information, hormone levels, cognitive performance, memory complaints, menopausal symptoms, health symptoms, quality-of-life ratings, and mood symptoms for the sample. Participants were aged 40 to 60 years (mean, 48.7 y), and all completed at least 12 years of education. Ninety-one percent of the participants were white, 6% were African American, and 2% were Asian. Two percent of the sample described their ethnicity as Hispanic.
One-way analysis of variance revealed that the groups significantly differed in age (F = 8.675, P G 0.001) but not in education (F = 0.651, P = 0.584). Pearson_s product-moment correlations revealed that age was significantly positively correlated with verbal learning (r = 0.19, P = 0.044), and education was significantly correlated with several domain scores, including attention/working memory (r = 0.29, P = 0.002), executive function (r = 0.244, P = 0.008), verbal learning (r = 0.274, P = 0.003), and motor (r = 0.246, P = 0.008). Table 2 provides unadjusted composite cognitive domain scores as a function of reproductive aging stage. Women in early postmenopause performed worse than women in the late reproductive stage on verbal learning (B = j0.95, SE = 0.42, P = 0.02), verbal memory (B = j0.97, SE = 0.40, P = 0.02), and fine motor skills (B = j0.88, SE = 0.40, P = 0.03) composite scores. There was a trend for women in early postmenopause to perform worse than women in the late reproductive stage on the attention/working memory composite score, but this did not reach statistical significance (B = j0.60, SE = 0.34, P = 0.08). In addition, women in early postmenopause performed worse than women in the late menopausal transition stage on verbal learning (B = j0.93, SE = 0.33, P G 0.01), verbal memory (B = j0.80, SE = 0.32, P = 0.01), fine motor skills (B = j0.70, SE = 0.32, P = 0.03), and attention/working memory (B = j0.55, SE = 0.28, P = 0.04) composite scores (Fig. 1) . Women in the early menopausal transition stage did not differ from the late reproductive stage or the late menopausal transition stage on any of the cognitive composite scores.
Predictors of cognitive performance
Higher E 2 levels were associated with better performance on the fine motor skills composite (B = 0.002, SE = 0.0008, P = 0.02). E 2 was not a significant predictor of any other cognitive composite measure. Higher FSH levels (B = 0.008, SE = 0.004, P = 0.07) were marginally associated with better performance on the fine motor skills composite. Vasomotor, sleep, and anxiety symptoms were not significant predictors of any cognitive composite measure.
DISCUSSION
The aims of this study were to determine if cognitive function differs across stages of reproductive aging and to evaluate whether hormone levels, menopausal symptoms, or both (eg, E 2 , FSH, depression, anxiety, hot flashes, and sleep disturbance) predicted cognitive function during the transition. We predicted that women in the late menopausal transition and early postmenopausal stages would perform worse on cognitive tasks supported by the hippocampus and PFC than women in the late reproductive and early menopausal transition stages, and that lower levels of E 2 , increased depressive symptoms, increased anxiety symptoms, increased hot flashes, and poor sleep quality would all be associated with poorer cognitive performance. The primary finding from our study was that women in early postmenopause performed worse than those in the late reproductive and late menopausal transition stages on verbal learning, verbal memory, and motor tasks, and worse than those in late menopausal transition on measures of attention/ working memory. These differences were not explained by menopausal symptoms, mood, or hormone levels. All women in the early postmenopausal stage had been in that stage for less than 12 months. In comparison with our findings, SWAN showed a decrement in verbal memory and processing speed in late perimenopause that improved in the postmenopausal period and could not be explained by symptoms. 3, 6 Two factors may be important in explaining differences in outcomes between SWAN and the current study: criteria for staging menopause and time spent in the postmenopausal stage. In the current study, we used updated criteria to define stages of reproductive aging, 5 and those criteria differ from SWAN criteria. SWAN defined early perimenopause as decreased predictability of menses and shorter than 3 months of amenorrhea. In comparison, we defined early transition as persistent cycle irregularity, defined as a difference in the length of consecutive cycles of 7 days or more on at least two occasions in the prior 10 cycles. SWAN defined late perimenopause as 3 to 11 months of amenorrhea, and we defined late transition as an amenorrhea interval of 60 days or longer. Both studies defined postmenopause as beginning at the FMP. A second characteristic of our postmenopausal group that differs from SWAN is that the women in our postmenopausal group were in the first year after the FMP, corresponding to the first year of the 6-year STRAW +10 early postmenopause stage (+1a). In comparison, SWAN participants were in the postmenopausal stage from 0 to 5 years. 3 It is therefore probable that our postmenopausal group was at an earlier stage of postmenopause than the postmenopausal SWAN group. Longitudinal data from SWAN demonstrate that E 2 levels decline and FSH levels rise from 2 years before the FMP up to 2 years after the FMP and then plateau. 27 In this way, our postmenopausal group, being in the first year of the FMP, might be more similar to the SWAN Blate perimenopause[ stage than to the SWAN Bpostmenopausal[ stage.
It is notable that the one of the specific cognitive domains affected by reproductive aging stage was verbal memory. This finding is consistent with KIWI and SWANVtwo longitudinal studies that found an effect of perimenopausal stage on delayed verbal memory. 1, 3 In both studies, the differences in verbal memory were found as a failure to improve during repeated administrations of the same task, rather than a decline from prior performance. This failure to demonstrate a practice effect is a common focus of longitudinal cognitive studies and recognizes the considerable improvements on tests that emerge with practice. Practice effect results from increased familiarity with a test, or Blearning[ the test. Ongoing testing of our cohort will provide the longitudinal assessments needed to compare more directly with SWAN and KIWI.
We also found that attention/working memory and verbal learning were affected by reproductive aging stage. This finding supports our prediction that the specific cognitive domains affected in the menopausal transition are those supported by the hippocampus and the PFC, brain regions that are a putative target for the effects of estrogen. 9, 10 The hippocampus plays a critical role in verbal episodic memory, including memory encoding and storage. The PFC also plays a critical role in early memory processing and is consistently activated on tasks of memory encoding 28 and working memory. 29 In a study of perimenopausal women, we previously reported an association between reports of memory difficulties and performance on tasks supported by the PFC, such as attention, verbal encoding, and working memory. 16, 30 Taken together, these findings suggest that women_s concerns about their memory function during the menopausal transition are warranted, and that they might experience particular vulnerabilities in the year after the FMP.
Contrary to our prediction but consistent with some of the literature finding no effect of menopausal symptoms on cognition in the menopausal transition, we found that depression, anxiety, sleep disturbance, and vasomotor symptoms did not predict cognitive performance. This suggests that cognitive declines through the transition period are an independent process rather than a consequence or a correlate of sleep disruption or depression. It is presumed that cognitive declines in the menopausal transition are hormonally mediated. Peripheral hormone levels are an imperfect but acceptable marker of central nervous system levels; cerebrospinal fluid steroid levels are typically lower than circulating levels, and brain steroid hormone levels generally exceed circulating levels because of accumulation, synthesis, or both. 31 We found that neither FSH nor E 2 related to cognitive function. The exception was that E 2 predicted motor function in the present study, corroborating previous evidence that women perform better during phases of the menstrual cycle that correspond to high estrogen levels compared with phases characterized by low levels. 32 Menopause-related mood symptoms have been suggested to be related to hormonal fluctuations 33 rather than to absolute hormone levels. It is possible that the relationship with cognition is similar. Because this study did not measure fluctuations, it is possible that we missed an association between changes in hormones and performance on verbally mediated tasks. The fact that the worst cognitive performance was observed in the first 12 months after the FMP might be viewed as consistent with an influence of fluctuating hormone levels.
The present study has several limitations. We had a relatively small sample of high-functioning, highly educated women. It remains to be seen if these same findings can be generalized to a larger, more representative sample. Second, we did not have comparisons with women in the peak reproductive or late postmenopausal stage.
Finally, the staging of 17 women was based on recall of bleeding patterns because we did not have prospective calendars or diaries. It is possible that some of those women were misclassified based on recollection errors.
CONCLUSIONS
Cognitive function varies across the menopausal transition, with early postmenopause being a critical period during which subtle declines in attention/working memory, verbal learning, verbal memory, and fine motor speed and dexterity may be seen. Menopausal symptoms are not associated with cognitive performance, suggesting that cognitive declines are independent of these factors. A larger, longitudinal evaluation of the Rochester Investigation of Cognition Across Menopause cohort through the entire transition is underway to better clarify patterns of cognitive change and to suggest possible mechanisms for such changes.
